B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due
to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted …

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and
SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma …

Nanoscale robots have potential as intelligent drug delivery systems that respond to
molecular triggers,,,. Using DNA origami we constructed an autonomous DNA robot …

Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM).
T cells can be genetically modified to express chimeric antigen receptors (CARs), which are …

B-cell maturation antigen (BCMA) is a validated target for chimeric antigen receptor (CAR) T-
cell therapy in multiple myeloma (MM). Despite promising objective response rates, most …

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients
with systemic lupus erythematosus (SLE). Methods Patients with moderate‐to‐severe SLE …

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …

Purpose: Multiple myeloma is a usually incurable malignancy of plasma cells. New
therapies are urgently needed for multiple myeloma. Adoptive transfer of chimeric antigen …

Despite many recent advances in therapy, there is still no plateau in overall survival curves
in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach …

B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors,
is predominantly expressed on the surface of terminally differentiated B cells. BCMA is …